Search

Your search for "igc" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s

April 16, 2024

IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced that interim data from its phase 2 trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo. IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial

April 9, 2024

IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC Pharma’s lead therapeutic candidate […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company

March 27, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management company. According to the announcement, IGC Pharma entered into a share purchase agreement (“SPA”) with Bradbury comprised of IGC issuing 8,823,529 shares of unregistered common stock […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Interim Results from Phase 2 Study Evaluating Treatment to Reduce Alzheimer’s Agitation

March 21, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on the interim analysis of its ongoing phase 2 trial. The trial is focused on evaluating the company’s proprietary IGC-AD1 as a treatment for agitation in dementia from Alzheimer’s Disease (“AAD”). According to the announcement, the interim data indicates that the study demonstrates clinical and […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Benzinga Virtual Healthcare Summit 2024

March 20, 2024

IGC Pharma (NYSE American: IGC), a company focused on Alzheimer’s disease and developing innovative solutions to address this devastating illness, has announced that its CEO Ram Mukunda and Vice President Claudia Grimaldi will participate in a fireside chat at the Benzinga Virtual Healthcare Summit 2024. The event is slated to take place on March 20, […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Names Healthcare Leader to Board of Directors

March 13, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has appointed a new independent director to its board of directors. The company announced that healthcare veteran Terry Lierman has accepted the position. Lierman brings a rich background in healthcare to this new opportunity. He currently serves as cochair of the board of advisors at the Institute […]

Press Releases

HealthLynked Welcomes David Rosal as New Chief Financial Officer

March 13, 2024

NAPLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare network and services, is delighted to announce the appointment of David Rosal as its new Chief Financial Officer (CFO), effective March 18, 2024. With a distinguished career that spans over two decades, Rosal brings a […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports ‘Promising’ Results in Preclinical Studies Evaluating Drug Candidate for Alzheimer’s Treatment

February 28, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, reported on the results of preclinical studies evaluating its drug candidate TGR-63 as a treatment for Alzheimer’s disease. According to the report, the data showed enhanced memory function, including memory acquisition, consolidation and retrieval, in an Alzheimer’s mouse model. The preclinical studies included the use of two […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Spotlighted in Ascendiant Equity Analyst Report

February 23, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is featured in a recent analyst coverage research report issued by Ascendiant Capital Markets LLC. The report included a “buy” recommendation with a $3 price target. The company noted that all reports prepared by analysts that spotlight IGC Pharma reflect the views of those analysts and are […]

News Articles

Correlate Energy Corp. (CIPI) Anticipates Impressive Performance in 2024 Given Overall Global Shift to Renewable Energy Sources

February 22, 2024

As more people come to terms with the reality of climate change and the risks that come with it, there has been a massive shift to renewables across various social and economic sectors, at an increasing rate. This has presented new opportunities for companies such as Correlate Energy (OTCQB: CIPI), a publicly traded company capitalizing […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q3 2024 Financial Results, Reports Corporate Achievements

February 20, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting financial results and business updates for the third fiscal quarter of 2024, the period ended Dec. 31, 2023. Highlights of the report include the company receiving a patent from the European Patent Office covering a method for treating pain in humans and a patent from […]

Press Releases

Nextech3D.ai Featured in Syndicated Broadcast Highlighting Launch of Next Era of GPT AI 3D Solutions

February 20, 2024

LOS ANGELES, Feb. 20, 2024 (GLOBE NEWSWIRE) — via IBN — Nextech3D.ai (CSE: NTAR) (OTCQX: NEXCF) (FSE: 1SS), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls, Miele and others including major e-commerce platform integrations with Shopify, BigCommerce and WooCommerce, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data from Preclinical Studies Indicating Proprietary Drug Candidate Reduces Agitation in Alzheimer’s Mouse Model

February 1, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting additional positive results from preclinical studies investigating its newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer’s disease. The company had already shared study results indicating that TGR-63 shows potential to alleviate plaque burden in Alzheimer’s cell lines and animal models. New results exhibit […]

InvestorNewsBreaks

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing Proprietary Drug Candidate TGR-63 Reduces Plaque in Alzheimer’s

January 23, 2024

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is sharing details regarding its drug candidate TGR-63, which targets amyloid-beta plaque and has potential to improve Alzheimer’s disease treatment in a significant manner. According to the announcement, preclinical trial data shows TGRr-63 reduces plaque in Alzheimer’s. The company observed that “a key pathological marker of Alzheimer’s […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Activates ClinCloud in Phase 2b Alzheimer’s Trial

January 17, 2024

IGC Pharma (NYSE American: IGC) today announced that ClinCloud, a clinical research facility in Florida, has dosed its first patient as part of IGC’s ongoing phase 2b trial. The company is currently conducting the trial at twelve sites in the U.S. and Canada with IGC-AD1, a combination medicine with a CB1 receptor partial agonist with […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Milestone’ Patent for Drug Formulation Used to Treat Agitation in Alzheimer’s

December 19, 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a patent from Divisional Direction of Patents, Mexico. The agency issued a Granting Office Action (“GOA”) for IGC Pharma’s treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.” According to the announcement, the company believes that the success of the patent in […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Biotech Showcase and BioPartnering @ JPM

December 13, 2023

IGC Pharma (NYSE American: IGC) has announced that its management team will participate in Biotech Showcase and BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2024. The presentation at Biotech Showcase is slated to begin at 2 p.m. PT on Jan. 8, 2024, while the BIO Partnering […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Partners with Prominent Center to Integrate AI into Clinical Trials

December 6, 2023

IGC Pharma (NYSE American: IGC) is collaborating with the Los Andes University Center for Research and Training in Artificial Intelligence (“CINFONIA”) in a partnership designed to leverage generative artificial intelligence (“AI”) to analyze variations in disease signatures among patients. The collaboration will provide key data to help identify individuals more likely to respond to treatment. IGC is […]

InvestorNewsBreaks

InvestorNewsBreaks — Cool Amps Corp.’s CEO and Director Help Show That the Path to a Climate-Friendlier Future ‘Goes Through Chapel Street’

December 4, 2023

Cool Amps was featured in a recent article published by New Haven Independent. The piece covers the recent Tech Hub Grand Opening, discussing Cool Amps’ Lonnie Garris III and Nick Anderson’s attendance at the event in New Haven, Connecticut, celebrating “less carbon, more innovation,” where they showcased their company’s “laminar flow extraction module” prototype. “Retired […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Enters Strategic Collaboration to Advance AI Initiatives

November 21, 2023

IGC Pharma (NYSE American: IGC) has announced its entry into a master cooperation agreement with the University of Los Andes for the development and adoption of generative AI solutions into the company’s drug identification, development and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including streamlining clinical trial efficiency, enhancing […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q2 2024 Financial, Corporate Report

November 13, 2023

IGC Pharma (NYSE American: IGC) is reporting financial and business results for second quarter 2023, the period ending Sept. 30, 2022. Highlights of the report include revenue in second quarter FY2024 increasing 44%, totaling an estimated $291,000 compared to the same quarter in FY2023, which was reported at approximately $202,000, with revenue in the first six months […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Cannabinoid-Based Topical Pain-Relief Treatment Receives European Patent

October 20, 2023

IGC Pharma (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, has achieved a significant milestone; the company has received notice from the European Patent Office that the patent for its proprietary “Cannabinoid Composition and Method for Treating Pain” has been granted. According to the announcement, the patent covers IGC Pharma’s pioneering method for treating pain […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report

August 14, 2023

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain, is reporting on its financial and business results for the first quarter of the 2024 fiscal year, the period ended June 30, […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Expands Phase 2 Trial to Add New Site

August 2, 2023

IGC Pharma (NYSE American: IGC) today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of its ongoing phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease. According to clinicaltrials.gov, IGC-AD1 is the only natural […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Presenting 6 Posters on Its Lead Therapeutic Candidate at AAIC 2023

July 18, 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced that it is presenting six in-person posters highlighting data from its phase 1 clinical trials investigating the company’s lead therapeutic candidate, IGC-AD1, at the Alzheimer’s Association International Conference (“AAIC”). The event is taking place July 16-20, 2023, in Amsterdam, Netherlands. “We are honored to […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Financial Results for Fiscal 2023

July 12, 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials,” said Ram Mukunda, CEO of IGC. “IGC-AD1 is delivering strong results […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Secures $12M Line of Credit to Strengthen Efforts in Alzheimer’s Research

July 7, 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co. Ltd. The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research. Bradbury Asset Management (Hong Kong) Limited, a Hong Kong headquartered financial institution managing approximately […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces $3M Common Stock Private Placement

July 6, 2023

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain, has received strategic investment support. According to an announcement from the company, it has received investments from four funds managed by Bradbury […]

Press Releases

ROTH MKM to Host 9th Annual London Conference on June 20-22, 2023

June 13, 2023

NEWPORT BEACH, Calif., June 13, 2023 (GLOBE NEWSWIRE) — via IBN — ROTH MKM (“Roth”), www.roth.com, will host the 9th Annual Roth London Conference on June 20-22, 2023, at Four Seasons Hotel London at Park Lane in London, UK. This event will provide institutional investors the unique opportunity to meet with C-suite leaders and executive management teams from approximately 70 […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives Notice of Allowance for Patent on IGC-501

June 6, 2023

IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an intent to grant from the European Patent Office. With these and a previous award, the […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) Advisor and Inventor of TGR-63 Receives National Technology Award

June 5, 2023

IGC Pharma (NYSE American: IGC) today announced recognition of its advisor, Professor T. Govindaraju, the inventor of the investigational Alzheimer’s drug candidate, TGR-63. According to the announcement, Govindaraju received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding Contribution in Commercializing Innovative Indigenous Technologies” from the Minister of State for Science and Technology […]

InvestorNewsBreaks

InvestorNewsBreaks — Infobird Co. Ltd. (NASDAQ: IFBD) Announces Integration of ChatGPT in ‘Milestone’ Upgrade of AI Customer Service System

April 24, 2023

Infobird (NASDAQ: IFBD), a leading provider of AI-powered customer-engagement solutions in China, recently integrated ChatGPT in its ongoing commitment to upgrade its artificial intelligence customer service system. According to the announcement, ChatGPT is a leading AIGC technologies that has been widely applied in fields such as natural language processing and machine learning. The company noted that […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Participation in Upcoming Planet MicroCap Showcase

April 18, 2023

IGC Pharma (NYSE American: IGC) will be presenting at this month’s Planet MicroCap Showcase: VEGAS 2023; the event is slated for Wednesday, April 26, 2023, at 7:30 p.m. ET. According to the announcement, IGC Pharma CEO Ram Mukunda and principal financial officer Claudia Grimaldi will be hosting the presentation; the session will include time for […]

InvestorNewsBreaks

InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Attend Investor Summit

March 22, 2023

IGC Pharma (NYSE American: IGC) (aka India Globalization Capital Inc.) today announced that its Chief Executive Officer Ram Mukunda and Principle Financial Officer Claudia Grimaldi will attend the Investor Summit on Wednesday, March 29, 2023. According to the update, Mukunda and Grimaldi will deliver a virtual company presentation at 11:30 a.m. ET and be available […]

News Articles

India Globalization Capital Inc. (NYSE American: IGC) Reports Triple-Digit Revenue Growth, Phase 2 Study Highlights in Q3 2023 Report

March 21, 2023

In a fragile economic environment, the third-quarter 2023 financial results reported by India Globalization Capital (NYSE American: IGC) are particularly remarkable. The company, which is pursuing effective treatment for Alzheimer’s patients suffering with agitation and other neuropsychiatric symptoms, released a report showing an increase in net revenue of 133% for the three-month period ending Dec. […]

InvestorNewsBreaks

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Rebrands, Including Changing Name to IGC Pharma, as Part of ‘Major Milestone’ Alignment

March 20, 2023

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) will begin operating under the name IGC Pharma Inc. (dba IGC), effective March 30, 2023; the name change is one aspect of the company’s rebranding strategy designed to better reflect its strategic focus and vision for the future. IGC’s common stock will trade on NYSE American exchange […]

Press Releases

IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.

March 20, 2023

POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) — India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the […]

InvestorNewsBreaks

InvestorNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

March 10, 2023

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).